When will Rubicatin (Rubitidine) be launched in the country? Drug launch progress and patient purchase

Lubicatin (Lurbinectedin) is an anti-tumor drug developed by PharmaMar. It is mainly used to treat malignant tumors such as small cell lung cancer. The drug received accelerated approval from the U.S. FDA in 2020 and has since been gradually promoted in many countries and regions around the world. According to the latest news, the original drug Rubicatin has been officially approved for marketing in mainland China, bringing more treatment options to patients in need. Despite this, the specific domestic selling price has not yet been disclosed. It is expected that the pricing may refer to the international market level, and it is still a relatively high-priced targeted therapy drug.

Before Rubicatin is fully distributed in pharmacies of major hospitals, patients who need medication can still consider purchasing it through formal overseas channels. Currently, the original version of Rubicatin can be purchased in Hong Kong. The specification is 4mg/ box. The price is about 2 more than 10,000 yuan. The price may fluctuate due to factors such as exchange rates and circulation costs. In addition, it has also been listed in other overseas markets, such as the United States and Singapore. The original drug in the United States costs more than 90,000 yuan per box, while the Singapore version is relatively cheaper. The price per box is about 3 yuan, and the overall price is still at a relatively high level.

It is worth noting that as of now, there is no generic version of Rubicatin available globally. Since its patent protection has not yet expired and the threshold for R&D and production is high, only original research drugs are currently available on the market. This also means that if patients choose to purchase drugs overseas, they can only purchase original research products, which are relatively expensive. For patients with greater financial pressure, they can pay attention to the news of whether generic drugs will be launched in the future, so as to obtain the same quality treatment at a more affordable price.

Overall, the domestic launch of Rubicatin is undoubtedly an important development in the field of domestic small cell lung cancer treatment. However, as prices have not yet been clarified and sales channels have not yet been fully rolled out, some patients may still need to rely on overseas channels to purchase drugs. It is recommended that patients consult their attending doctor in detail before purchasing drugs to understand drug indications and treatment plans, and obtain drugs through formal channels to avoid purchasing fake and shoddy products. As more patients benefit from such new targeted drugs, their prices may become more transparent and reasonable in the future.

Reference materials:https://www.zepzelca.com/